153 related articles for article (PubMed ID: 6199316)
1. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank.
Ritts RE; Del Villano BC; Go VL; Herberman RB; Klug TL; Zurawski VR
Int J Cancer; 1984 Mar; 33(3):339-45. PubMed ID: 6199316
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72).
Klug TL; Sattler MA; Colcher D; Schlom J
Int J Cancer; 1986 Nov; 38(5):661-9. PubMed ID: 2429934
[TBL] [Abstract][Full Text] [Related]
3. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
[TBL] [Abstract][Full Text] [Related]
4. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.
Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K
J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396
[TBL] [Abstract][Full Text] [Related]
5. The value of CA 19-9 in gastric and colorectal carcinoma.
Safi F; Bittner R; Roscher R; Kübel R; Beger HG
Cancer Invest; 1987; 5(5):401-7. PubMed ID: 3480768
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Ca 12-5 as a tumor marker for gastric and colo-rectal cancer in comparison to CEA and Ca 19-9.
Quentmeier A; Schlag P; Geisen HP; Schmidt-Gayk H
Eur J Surg Oncol; 1987 Jun; 13(3):197-201. PubMed ID: 3474158
[TBL] [Abstract][Full Text] [Related]
7. Significance of measurement of a carbohydrate antigenic determinant 19-9 (CA 19-9) for monitoring colorectal cancer patients.
Tomoda H; Furusawa M
Jpn J Surg; 1986 Jan; 16(1):73-5. PubMed ID: 2421035
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of M43: a novel cancer-associated mucin epitope.
Goodgame R; Kiefe C; Rose E; Sutton F; Brown J; Alpert E
Cancer Res; 1993 Jun; 53(12):2803-9. PubMed ID: 7684947
[TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnostics of gastrointestinal malignancies.
Heptner G; Domschke S; Domschke W
Scand J Gastroenterol; 1989 Aug; 24(6):745-50. PubMed ID: 2814339
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of the tumor markers CEA and CA 19-9 in colorectal diagnosis].
Heptner G; Domschke S; Krapf F; Schneider MU; Iro H; Domschke W
Dtsch Med Wochenschr; 1984 Aug; 109(35):1309-12. PubMed ID: 6590287
[TBL] [Abstract][Full Text] [Related]
12. The significance of CA19-9 tumor antigen in the serum of patients with carcinomas.
Wang FM; Tsai LC; Chang ZN; Han SH; Tsao D
Proc Natl Sci Counc Repub China B; 1985 Apr; 9(2):119-25. PubMed ID: 3863154
[TBL] [Abstract][Full Text] [Related]
13. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies.
Yoshikawa T; Nishida K; Tanigawa M; Fukumoto K; Kondo M
Digestion; 1985; 31(2-3):67-76. PubMed ID: 2581838
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases.
Kuusela P; Jalanko H; Roberts P; Sipponen P; Mecklin JP; Pitkänen R; Mäkelä O
Br J Cancer; 1984 Feb; 49(2):135-9. PubMed ID: 6582896
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of CA 19-9 (carbohydrate antigen) in gastrointestinal adenocarcinoma.
Mennini G; Silecchia G; Zanna C; Cucchiara G; Spadaro G; Greco E; Basoli A; Speranza V
Ital J Surg Sci; 1985; 15(1):37-43. PubMed ID: 3858272
[TBL] [Abstract][Full Text] [Related]
16. [Assay of serum carbohydrate antigen (CA) 19-9 in the diagnosis of gastric cancer].
Nishida K; Yamamoto T; Yoshioka K; Iida M; Miyagawa H; Yoshikawa T; Sugino S; Kondo M
Gan To Kagaku Ryoho; 1986 Jan; 13(1):101-8. PubMed ID: 3455804
[TBL] [Abstract][Full Text] [Related]
17. The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
Staab HJ
Acta Gastroenterol Belg; 1987; 50(1):29-35. PubMed ID: 3480668
[No Abstract] [Full Text] [Related]
18. Measurement of a pancreatic cancer-associated antigen (DU-PAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers.
Sawabu N; Toya D; Takemori Y; Hattori N; Fukui M
Int J Cancer; 1986 May; 37(5):693-6. PubMed ID: 3457770
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of CA 19-9 for the detection of malignant tumors--a comparison with CEA and IAP].
Furukawa M; Kazaka S; Kushibiki K; Ashida Y; Saito H; Yamamoto H; Furukawa T
Gan No Rinsho; 1984 Apr; 30(4):357-62. PubMed ID: 6587133
[TBL] [Abstract][Full Text] [Related]
20. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen.
Bast RC; Klug TL; Schaetzl E; Lavin P; Niloff JM; Greber TF; Zurawski VR; Knapp RC
Am J Obstet Gynecol; 1984 Jul; 149(5):553-9. PubMed ID: 6204531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
